Your AI-Trained Oncology Knowledge Connection!
The CYTOSHRINK trial showed that incorporating stereotactic body radiation therapy (SBRT) with ipilimumab and nivolumab did not enhance progression-free survival and resulted in a shorter median PFS compared to immunotherapy alone for advanced renal cell carcinoma.
Long-term CheckMate 9ER results show deeper tumor shrinkage with cabozantinib plus nivolumab and predicts longer survival and durable responses in advanced renal cell carcinoma.
An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.
A phase 3 trial evaluating TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) showed positive safety and toxicity profile in prostate cancer.
Academic centers are associated with greater biliary tract cancer surgery success while minority patients and nonacademic care face gaps, urging better resource allocation.
IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.
A supplemental Biologics License Application has been submitted for nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors.
Results from the 992-patient study will be presented at an upcoming medical meeting; FDA review of giredestrant is ongoing based on data from the positive evERA trial.
Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.
The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.
Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.
PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.
ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.
FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.
New data push ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategy.
The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.
FDA’s February oncology surge brings new pancreatic TTFields, PD-1 win in ovarian cancer, AI tools, and key trial setbacks.
The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring but efficacy came with increased toxicity.
Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.
During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.
Hi-C on routine FFPE biopsies uncovers hidden lymphoma drivers, enhancer hijacking, and PD-L1 rearrangements, guiding targeted therapy beyond FISH.
Phase 2a data show oral namodenoson is well tolerated in heavily pretreated pancreatic cancer, with survival follow-up ongoing and FDA orphan status boosting promise.
The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.
The FDA has granted a priority review and accepted the NDA for rusfertide in PV.
In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.
During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.
Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.
Adding nivolumab/ipilimumab to liver-directed melphalan improved outcomes in patients with metastatic uveal melanoma.
Induction ipilimumab/nivolumab plus chemoradiotherapy consolidation was associated with bladder preservation in muscle-invasive urothelial carcinoma.
Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.
